CPMV Pengajuan SEC - Mosaic ImmunoEngineering, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

836564

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Mosaic ImmunoEngineering, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 19, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000
August 12, 2025	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K ☐ Transition Report on For
May 20, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00
May 15, 2025	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K ☐ Transition Report on Fo
April 15, 2025	EX-21	List of subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Mosaic ImmunoEngineering Development Company Patriot Data Solutions Group, Inc. Delaware California
April 15, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 MOSAIC IMMUNOENGINEERING, INC.
March 28, 2025	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K ☐ Transition Report on
January 2, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2024 MOSAIC IMMUNOENGINEERING, INC.
January 2, 2025	EX-10.1	Term Extension Letter dated December 31, 2024 Exhibit 10.1 December 31, 2024 Oncotelic Therapeutics, Inc. Vuong Trieu 29397 Agoura Rd, Suite 107 Agoura Hills, CA 91301 Dear Vuong: This letter, together with the previously executed binding term sheet dated April 26, 2024 (the “Term Sheet”) and attached hereto, which set forth our mutual understanding regarding a possible business relationship referred to as the “Transaction” between Mosaic Imm
November 19, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
November 13, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 000-22182 (Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 1
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-2
July 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 23, 2024 MOSAIC IMMUNOENGINEER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 23, 2024 MOSAIC IMMUNOENGINEERING, INC.
May 31, 2024	EX-10.1	Employment status change letter dated May 31, 2024 Exhibit 10.1 Employee Status Change May 31, 2024 Mr. Paul Lytle EVP, Chief Financial Officer Mosaic ImmunoEngineering, Inc. Dear Mr. Lytle: This letter is to confirm that your employment status with Mosaic ImmunoEngineering, Inc. (the “Company”) will change from full time exempt to part-time effective June 1, 2024. Below are some additional details pertaining to your revised employment status: Pos
May 31, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2024 MOSAIC IMMUNOENGINEERING, INC.
May 21, 2024	EX-16.1	KMJ Letter submitted to the Securities and Exchange Commission dated May 21, 2024 Exhibit 16.1 May 21, 2024 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N. E. Washington, D.C. 20549 Ladies and Gentlemen: We have read the comments made regarding us in Item 4.01 of Form 8-K of Mosaic ImmunoEngineering, Inc. dated May 21, 2024, and are in agreement with those statements. /s/ KMJ Corbin & Company LLP Irvine, California cc: Mr. Robert Baffi, Ph.D.
May 21, 2024	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2024 MOSAIC IMMUNOENGINEERING, INC.
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-
May 14, 2024	EX-10.2	Unsecured convertible note purchase agreement dated May 8, 2024 by and between Company and Oncotelic Therapeutics, Inc. Exhibit 10.2 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (“Agreement”) is made as of May 8, 2024 by and among Mosaic ImmunoEngineering, Inc, a Delaware corporation (“Company”), and Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc. and now the “Lender”). Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Notes (as defi
April 29, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2024 MOSAIC IMMUNOENGINEERING, INC.
April 29, 2024	EX-99.1	Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc. —The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and acc Exhibit 99.1 Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc. —The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic’s AI platform for identifying immunotherapy combinations — Huntington Beach, Calif., April 29, 2024 – Mosaic ImmunoEngin
April 29, 2024	EX-10.1	Binding Term Sheet by and between Company and Oncotelic Therapeutics, Inc. dated April 26, 2024 Exhibit 10.1 CONFIDENTIAL April 26, 2024 Oncotelic Therapeutics, Inc. Vuong Trieu 29397 Agoura Rd, Suite 107 Agoura Hills, CA 91301 Dear Vuong: This letter, together with the attached binding term sheet attached hereto, sets forth our mutual understanding regarding a possible commercial relationship referred to as the “Transaction” between Mosaic ImmunoEngineering, Inc., a Delaware corporation (“M
April 19, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2024 MOSAIC IMMUNOENGINEERING, INC.
April 15, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 MOSAIC IMMUNOENGINEERING, INC.
April 15, 2024	EX-21	List of subsidiaries of the Company Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Mosaic ImmunoEngineering Development Company Delaware Patriot Data Solutions Group, Inc. California
March 28, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K ☐ Transition Report on
March 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2024 MOSAIC IMMUNOENGINEE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2024 MOSAIC IMMUNOENGINEERING, INC.
November 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-2
June 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2023 MOSAIC IMMUNOENGINEER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2023 MOSAIC IMMUNOENGINEERING, INC.
June 26, 2023	EX-10.1	Amendment No. 1 to Redemption Agreement by and between Mosaic ImmunoEngineering, Inc. and Holocom, Inc. dated June 21, 2023 Exhibit 10.1 Amendment No. 1 to Series A Preferred Stock Redemption Agreement THIS Amendment No. 1 to the Series A Preferred Stock Redemption Agreement (the “Amendment No. 1”) is made this 21st day of June, 2023 (“Effective Date”) by and among (i) Mosaic ImmunoEngineering, Inc., a Delaware corporation ("Mosaic"), f/k/a Patriot Scientific Corporation and (ii) Holocom, Inc., a California corporation
May 12, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2023 MOSAIC IMMUNOENGINEERIN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2023 MOSAIC IMMUNOENGINEERING, INC.
March 2, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 MOSAIC IMMUNOENGINEERING, INC.
March 2, 2023	EX-21.1	List of subsidiaries of the Company Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Mosaic ImmunoEngineering Development Company Patriot Data Solutions Group, Inc. Delaware California
December 28, 2022	RW	Mosaic ImmunoEngineering, Inc. 1537 South Novato Blvd, #5 Novato, California 94947 RW 1 mosaicrw.htm FORM RW Mosaic ImmunoEngineering, Inc. 1537 South Novato Blvd, #5 Novato, California 94947 December 28, 2022 VIA E-MAIL AND EDGAR SUBMISSION Securities and Exchange Commission Attention: Mr. David Gessert, Staff Attorney Division of Corporate Finance 100 F Street N.W. Washington, D.C. 20549 Re: Mosaic ImmunoEngineering, Inc. - Withdrawal of Registration Statement on Form S-1, Fil
November 1, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-2
August 4, 2022	EX-10.1	License Agreement by and between Mosaic ImmunoEngineering, Inc. and Case Western Reserve University dated May 4, 2022 Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENSE AGREEMENT Case Western Reserve University – Mosaic ImmunoEngineering, Inc. This License Agreement (hereinafter “Agreement”) entered into as of thi
July 12, 2022	EX-10.1	Redemption Agreement by and between Mosaic ImmunoEngineering, Inc. and Holocom, Inc. dated July 6, 2022 Exhibit 10.1 Series A Preferred Stock Redemption Agreement THIS SERIES A PREFERRED STOCK REDEMPTION AGREEMENT (the "Redemption Agreement") is made this 6th day of July, 2022 (?Effective Date?)by and among (i) Mosaic ImmunoEngineering, Inc., a Delaware corporation ("Mosaic"), f/k/a Patriot Scientific Corporation and (ii) Holocom, Inc., a California corporation (?Holocom?) (collectively referred to
July 12, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 6, 2022 MOSAIC IMMUNOENGINEERING, INC.
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-
May 5, 2022	EX-99.1	Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University —The licensed technology was jointly invented by researchers at Case Western Reserve University and Dartmouth College— —The l Exhibit 99.1 Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University ?The licensed technology was jointly invented by researchers at Case Western Reserve University and Dartmouth College? ?The license covers the use of plant viruses such as cowpea mosaic virus (CPMV) for the treatment of cancer in both human and companion animals
May 5, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 MOSAIC IMMUNOENGINEERING, INC.
February 22, 2022	EX-10.1	Form of Convertible Note Purchase Agreement dated February 18, 2022 EX-10.1 2 mosaicex1001.htm FORM OF CONVERTIBLE NOTE PURCHASE AGREEMENT Exhibit 10.1 Form of Convertible Note Purchase Agreement This Convertible Note Purchase Agreement (the “Agreement”) dated as of [Month] [Day], 2022 (the “Effective Date”) among: (a) MOSAIC IMMUNOENGINEERING, INC., a Delaware corporation (the “Company”) and (b) And the persons and entities (each individually a “Purchaser,” and c
February 22, 2022	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 18, 2022 MOSAIC IMMUNOENGINEERING, INC.
February 4, 2022	S-1	As filed with the Securities and Exchange Commission on February 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 3, 2022 Registration No.
February 4, 2022	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables ???????????S-1????????? (Form Type) ????????????????Mosaic ImmunoEngineering, Inc.
January 26, 2022	EX-21.1	List of subsidiaries of the Company Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Mosaic ImmunoEngineering Development Company Patriot Data Solutions Group, Inc. Delaware California
January 26, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 MOSAIC IMMUNOENGINEERING, INC.
November 2, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q iTable of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 3, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-2
June 25, 2021	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement MOSAIC IMMUNOENGINEERING INC. (Exact name of reg
June 15, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2021 MOSAIC IMMUNOENGINEERING INC.
June 15, 2021	EX-99.1	Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors --Experience in the Development of Biotechnology and Viral Based Therapeutics Will Help Enhance the Development of the Company's Pipe Exhibit 99.1 Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors -Experience in the Development of Biotechnology and Viral Based Therapeutics Will Help Enhance the Development of the Company's Pipeline- Novato, California, June 15, 2021 ? Mosaic ImmunoEngineering Inc. (?Mosaic? or the ?Company?), (OTCQB: CPMV), a development-stage bi
June 15, 2021	PRE 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement MOSAIC IMMUNOENGINEERING INC. (Exact name of reg
May 10, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2021 MOSAIC IMMUNOENGINEERING INC.
May 10, 2021	EX-10.1	Form of Convertible Note Purchase Agreement Exhibit 10.1 Form of Convertible Note Purchase Agreement This Convertible Note Purchase Agreement (the ?Agreement?) dated as of [], 2021 (the ?Effective Date?) among: (a) MOSAIC IMMUNOENGINEERING INC., a Delaware corporation (the ?Company?) and (b) And the persons and entities (each individually a ?Purchaser,? and collectively, the ?Purchasers?) named on the Schedule of Purchasers attached hereto
May 5, 2021	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-
May 5, 2021	EX-10.1	Consulting agreement signed April 29, 2021 by and between Registrant and Dr. Nicole Steinmetz EX-10.1 2 mosaic10q-ex1001.htm CONSULTING AGREEMENT Exhibit 10.1 MOSAIC IMMUNOENGINEERING INC. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is effective as of August 31, 2020 (the “Effective Date”) by and between Mosaic ImmunoEngineering Inc., a Delaware corporation having its principal place of business located at 1537 South Novato Blvd #5, Novato, CA 94947 (“Company”), and Nicole
March 9, 2021	S-8	- FORM S-8 As filed with the Securities and Exchange Commission on March 9, 2021 Registration No.
March 2, 2021	EX-10.6	Form of Incentive Stock Option Award Agreement under the 2020 Omnibus Incentive Plan Exhibit 10.6 MOSAIC IMMUNOENGINEERING INC. 2020 OMNIBUS INCENTIVE PLAN NOTICE OF INCENTIVE STOCK OPTION Mosaic ImmunoEngineering Inc., a Delaware corporation (the ?Company?) grants to you the following Incentive Stock Option to purchase Shares of the common stock of the Company, par value $0.00001 per share, pursuant to the Company?s 2020 Omnibus Incentive Plan (the ?Plan?) and the attached Incent
March 2, 2021	EX-10.11	Form of Indemnification Agreement by and between the Company and the Officers and Board of Directors of the Company Exhibit 10.11 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [], by and between Mosaic ImmunoEngineering Inc., a Delaware corporation (the ?Company?), and [], (?Indemnitee?). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly held corporations as directors, officers, consultants or in other capacities unless they ar
March 2, 2021	EX-10.5	Code of Business Conduct and Ethics, as adopted on November 3, 2020 Exhibit 10.5 MOSAIC IMMUNOENGINEERING INC. CODE OF BUSINESS CONDUCT AND ETHICS Adopted November 3, 2020 INTRODUCTION This Code of Business Conduct and Ethics (?Code?) is designed to deter wrongdoing and to promote: ? honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; ? full, fair, accurate, timely
March 2, 2021	EX-10.7	Form of Non-Qualified Stock Option Award Agreement under the 2020 Omnibus Incentive Plan Exhibit 10.7 MOSAIC IMMUNOENGINEERING INC. 2020 OMNIBUS INCENTIVE PLAN NOTICE OF NON-QUALIFIED STOCK OPTION Mosaic ImmunoEngineering Inc., a Delaware corporation (the ?Company?) grants to you the following Non-Qualified Stock Option to purchase Shares of the common stock of the Company, par value $0.00001 per share, pursuant to the Company?s 2020 Omnibus Incentive Plan (the ?Plan?) and the attache
March 2, 2021	EX-10.8	Form of Restricted Stock Award Agreement under the 2020 Omnibus Incentive Plan Exhibit 10.8 MOSAIC IMMUNOENGINEERING INC. 2020 OMNIBUS INCENTIVE PLAN NOTICE OF RESTRICTED STOCK Mosaic ImmunoEngineering Inc., a Delaware corporation (the ?Company?) grants to you the following Restricted Stock pursuant to the Company?s 2020 Omnibus Incentive Plan (the ?Plan?) and the attached Restricted Stock Award Agreement (the ?Award Agreement?): Participant: [insert name] Total Shares of Re
March 2, 2021	EX-21	List of subsidiaries of the Company Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Mosaic ImmunoEngineering Development Company Delaware Patriot Data Solutions Group, Inc. California
March 2, 2021	EX-10.10	Form of Stock Appreciation Rights Award Agreement under the 2020 Omnibus Incentive Plan Exhibit 10.10 MOSAIC IMMUNOENGINEERING INC. 2020 OMNIBUS INCENTIVE PLAN NOTICE OF STOCK APPRECIATION RIGHTS Mosaic ImmunoEngineering Inc., a Delaware corporation (the ?Company?) grants to you the following Stock Appreciation Rights (?SARs?), pursuant to the Company?s 2020 Omnibus Incentive Plan (the ?Plan?) and the attached Stock Appreciation Rights Award Agreement (the ?Award Agreement?): Partici
March 2, 2021	EX-10.9	Form of Restricted Stock Unit Award Agreement under the 2020 Omnibus Incentive Plan Exhibit 10.9 MOSAIC IMMUNOENGINEERING INC. 2020 OMNIBUS INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNITS Mosaic ImmunoEngineering Inc., a Delaware corporation (the ?Company?) grants to you the following Restricted Stock Units (?RSUs?), pursuant to the Company?s 2020 Omnibus Incentive Plan (the ?Plan?) and the attached Restricted Stock Unit Award Agreement (the ?Award Agreement?): Participant: [inse
March 2, 2021	10-KT	- FORM 10-KT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from June 1, 2020 to December 31, 2020 Commission File Number 0-22182 MOSAIC IMMUNOENGINEERING INC.
January 25, 2021	CORRESP	- January 25, 2021 VIA EDGAR Mr. David Gessert Mr. Tim Buchmiller U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Re: Mosaic ImmunoEngineering Inc. Amendment No. 1 to Registration Statement on Form S-3/A File No. 333-251261 Dear Messrs. Gessert and Buchmiller: Mosaic ImmunoEngineering Inc. (the “Company”) hereby
January 21, 2021	CORRESP	- CORRESP 1 filename1.htm NEW YORK LONDON SINGAPORE PHILADELPHIA CHICAGO WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO LOS ANGELES TAIWAN BOSTON HOUSTON AUSTIN HANOI HO CHI MINH CITY FIRM and AFFILIATE OFFICES www.duanemorris.com SHANGHAI ATLANTA BALTIMORE WILMINGTON MIAMI BOCA RATON PITTSBURGH NEWARK LAS VEGAS CHERRY HILL LAKE TAHOE MYANMAR ALLIANCES IN MEXICO AND SRI LANKA VIA EDGAR Januar
January 21, 2021	S-3/A	- AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on January 21, 2021 Registration No.
December 30, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2020 MOSAIC IMMUNOENGINEERING INC.
December 29, 2020	EX-10.3	Offer Letter, dated November 13, 2020, by and between the Registrant and Mr. Steven King Exhibit 10.3 November 13, 2020 Mr. Steven King Dear Steve, Mosaic ImmunoEngineering Inc. (the “Company”) was founded to advance life changing cancer therapies for human and companion animal patients with cancer while simultaneously advancing a unique vaccine platform with potential across many diseases. The key to our success is a talented team that will be at the center of establishing and execut
December 29, 2020	10-Q	Quarterly Report - QUARTERLY REPORT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2020 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num
December 29, 2020	EX-10.4	Offer Letter, dated November 13, 2020, by and between the Registrant and Mr. Paul Lytle Exhibit 10.4 November 13, 2020 Mr. Paul Lytle Dear Paul, Mosaic ImmunoEngineering Inc. (the “Company”) was founded to advance life changing cancer therapies for human and companion animal patients with cancer while simultaneously advancing a unique vaccine platform with potential across many diseases. The key to our success is a talented team that will be at the center of establishing and executin
December 10, 2020	S-3	As filed with the Securities and Exchange Commission on December 10, 2020 As filed with the Securities and Exchange Commission on December 10, 2020 Registration No.
December 8, 2020	SC 13D	PTSC / Patriot Scientific Corp. / Case Western Reserve University - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.
December 1, 2020	EX-3.2	Amended and Restated Bylaws of Mosaic ImmunoEngineering Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MOSAIC IMMUNOENGINEERING INC. (formerly known as Patriot Scientific Corporation) Incorporated under the Laws of the State of Delaware Date of Adoption: October 22, 2020 ARTICLE I Offices Section 1.01 Offices. The address of the registered office of Mosaic ImmunoEngineering Inc. (hereinafter called the "Corporation") in the State of Delaware shall be at 16
December 1, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 30, 2020 MOSAIC IMMUNOENGINEERING INC.
December 1, 2020	EX-4.1	Specimen of Common Stock Certificate of Mosaic ImmunoEngineering Inc. Exhibit 4.1
December 1, 2020	EX-10.1	Press release dated December 1, 2020 Exhibit 10.1 Patriot Scientific Corporation Announces Name Change to ?Mosaic ImmunoEngineering Inc.?, Stock Symbol Change and Reverse Stock Split Novato, Calif, December 1, 2020 ? Patriot Scientific Corporation ("Patriot") (OTC PINK: PTSC) announced today that it has changed its name to ?Mosaic ImmunoEngineering Inc.?, (the ?Company? or ?Mosaic?) effective immediately. In addition, the Company wil
December 1, 2020	EX-3.1	Amended and Restated Certificate of Incorporation of Mosaic ImmunoEngineering Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PATRIOT SCIENTIFIC CORPORATION Patriot Scientific Corporation (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware as set forth in Title 8 of the Delaware Code (the ?DGCL?), hereby certifies as follows: 1. The original Certificate of Incorporation of the Corporation (the
November 19, 2020	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K (Amendment No.
November 2, 2020	DEF 14C	2020 Omnibus Incentive Plan of Mosaic ImmunoEngineering Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement Patriot Scientific Corporation (Exact name of re
October 23, 2020	PRE 14C	- PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Patriot Scientific Corporation (Exact name of re
October 15, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2020 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
October 15, 2020	EX-10.14	Materials Transfer, Evaluation and Exclusion Option Agreement dated July 1, 2020 between Company and Case Western Reserve University Exhibit 10.14 MATERIALS TRANSFER, EVALUATION AND EXCLUSIVE OPTION AGREEMENT THIS AGREEMENT made this 1st day of July, 2020 (“Effective Date”) by and between Case Western Reserve University, an Ohio nonprofit corporation having a place of business at 10900 Euclid Avenue, Cleveland, Ohio 44106-7219 (referred to as “CWRU”) and Mosaic Immunoengineering Inc., a Delaware for-profit corporation, having a
October 14, 2020	EX-99.2	UNAUDITED PRO FORMA CONDENSED COMBINED FNANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FNANCIAL INFORMATION On August 19, 2020, Patriot Scientific Corporation, a Delaware corporation (the “Company” or “Patriot”) and privately held Mosaic ImmunoEngineering Inc. (“Private Mosaic”) entered into a stock purchase agreement (“Stock Purchase Agreement”). The transaction closed on August 21, 2020 (“Closing Date”) in accordance with the ter
October 14, 2020	8-K/A	Financial Statements and Exhibits - FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K (Amendment No.
October 14, 2020	EX-99.1	Mosaic ImmunoEngineering Inc. INDEX TO FINANCIAL STATEMENTS FOR the period MARCH 30, 2020 (date of inception) to MAY 31, 2020 Exhibit 99.1 Mosaic ImmunoEngineering Inc. INDEX TO FINANCIAL STATEMENTS FOR the period MARCH 30, 2020 (date of inception) to MAY 31, 2020 Page Report of Independent Registered Public Accounting Firm 2 Financial Statements: Balance Sheet 3 Statement of Operations 4 Statement of Stockholders’ Deficit 5 Statement of Cash Flows 6 Notes to Financial Statements 7 1 REPORT OF INDEPENDENT REGISTERED PUBL
August 25, 2020	EX-10.13	Stock Purchase Agreement dated August 19, 2020 among Patriot Scientific Corporation (now known as Mosaic ImmunoEngineering Inc.), PTSC Sub One Inc., private Mosaic ImmunoEngineering Inc., certain stockholders of private Mosaic ImmunoEngineering Inc. set forth therein, and Steven King EX-10.13 6 ptsiex1013.htm STOCK PURCHASE AGREEMENT Exhibit 10.13 STOCK PURCHASE AGREEMENT by and among PATRIOT SCIENTIFIC CORPORATION, as Parent PTSC SUB ONE, INC., as Buyer MOSAIC IMMUNOENGINEERING INC., as the Company THE STOCKHOLDERS OF THE COMPANY NAMED HEREIN, as the Sellers and STEVEN KING as the Sellers’ Representative Dated as of August 19, 2020 TABLE OF CONTENTS Page ARTICLE I PURCHASE OF
August 25, 2020	EX-3.3.11	Investor Rights Agreement dated August 19, 2020, among Company and holders of Series A and Series B Preferred Stock Exhibit 3.3.11 INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 3 2.1 Demand Registration 3 2.2 Company Registration 4 2.3 Underwriting Requirements 4 2.4 Obligations of the Company 5 2.5 Furnish Information 7 2.6 Expenses of Registration 7 2.7 Delay of Registration 7 2.8 Reports Under Exchange Act 7 2.9 “Market Stand-off” Agreement 8 2.10 Restrictions on
August 25, 2020	EX-3.3.9	Certificate of Designation of Series A Convertible Voting Preferred Stock (“Series A Preferred”) Exhibit 3.3.9 CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND LIMITATIONS OF THE SERIES A CONVERTIBLE VOTING PREFERRED STOCK OF PATRIOT SCIENTIFIC CORPORATION Patriot Scientific Corporation, a Delaware corporation, (the “Corporation”) DOES HEREBY CERTIFY: The Amended and Restated Certificate of Incorporation of the Corporation (the “Charter”) confers upon the Board of Directors of the Corpor
August 25, 2020	8-K	Regulation FD Disclosure, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 19, 2020 Patriot Scientific Corporation (Exact Name of Registrant as Specified in Charter) Delaware 0-22182 84-1070278 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
August 25, 2020	EX-3.3.12	Voting Agreement dated August 19, 2020, among Company and holders of Series A and Series B Preferred Stock Exhibit 3.3.12 PATRIOT SCIENTIFIC CORPORATION VOTING AGREEMENT TABLE OF CONTENTS Page 1. Vote to Increase Authorized Common Stock. 1 2. Vote for Reverse Stock Split. 2 3. Remedies. 2 3.1 Covenants of the Company. 2 3.2 Irrevocable Proxy and Power of Attorney. 2 3.3 Specific Enforcement. 3 3.4 Remedies Cumulative. 3 4. Term. 3 5. Miscellaneous. 3 5.1 Additional Parties. . 3 5.2 Transfers. 3 5.3 Suc
August 25, 2020	EX-3.3.10	Certificate of Designation of Series B Convertible Voting Preferred Stock (“Series B Preferred”) Exhibit 3.3.10 CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND LIMITATIONS OF THE SERIES B CONVERTIBLE VOTING PREFERRED STOCK OF PATRIOT SCIENTIFIC CORPORATION Patriot Scientific Corporation, a Delaware corporation, (the “Corporation”) DOES HEREBY CERTIFY: The Amended and Restated Certificate of Incorporation of the Corporation (the “Charter”) confers upon the Board of Directors of the Corpo
August 25, 2020	EX-99.1	Patriot Scientific Corporation and Mosaic ImmunoEngineering Inc. Enter into Definitive Merger Agreement Exhibit 99.1 Patriot Scientific Corporation and Mosaic ImmunoEngineering Inc. Enter into Definitive Merger Agreement Carlsbad and Novato, Calif., August 24, 2020 – Patriot Scientific Corporation (the “Company” or “Patriot”) (OTC PINK: PTSC) and Mosaic ImmunoEngineering Inc., (“Mosaic”) announced today that they have entered into a definitive agreement under which a wholly-owned subsidiary of Patri
August 24, 2020	EX-21	List of subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Patriot Data Solutions Group, Inc. California
August 24, 2020	10-K	Annual Report - ANNUAL REPORT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2020 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [] For the transition period from to Commission File Number 0-22182 PATR
April 8, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2020 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num
January 14, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2019 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num
October 11, 2019	10-Q	PTSC / Patriot Scientific Corp. 10-Q - Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2019 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
October 4, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 1, 2019 Patriot Scientific Corporation (Exact Name of Registrant as Specified in Charter) Delaware 0-22182 84-1070278 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
October 4, 2019	EX-10.1	Separation Agreement and General Release of All Claims between Patriot Scientific Corporation and Cliff Flowers as of October 1, 2019. Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS This Separation Agreement and General Release of All Claims (“Agreement”) is made by and between Patriot Scientific Corporation (the “Company”) and Clifford Flowers (“Employee”) (collectively referred to as the “Party” or “Parties” appropriately) as of the date the Parties have signed it below (the “Effective Date”), with respect
August 29, 2019	10-K	PTSC / Patriot Scientific Corp. 10-K - Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2019 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-22182 PA
August 29, 2019	EX-4.3	Description of Securities Exhibit 4.3 Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of August 29, 2019, Patriot Scientific Corporation, a Delaware corporation (the “Company”, “PTSC”, “we”, “us”, or “our”), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Common Stock, par value $.00001 per
August 29, 2019	EX-21	List of subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Patriot Data Solutions Group, Inc. California
April 15, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2019 Patriot Scientific Corporation (Exact Name of Registrant as Specified in Charter) Delaware 0-22182 84-1070278 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.
April 15, 2019	EX-10.1	Consulting Agreement effective as of April 12, 2019 between Patriot Scientific Corporation and Artius Bioconsulting. Exhibit 10.1 PATRIOT SCIENTIFIC CORPORATION, INC. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into effective as of April 12, 2019 the “Effective Date”) by and between Patriot Scientific Corporation, Inc., a Delaware Corporation (“PTSC”) (“Company”), and Artius Bioconsulting, a California limited liability company (“Consultant”). The Company desires to retain Consultant
April 15, 2019	10-Q	PTSC / Patriot Scientific Corp. QUARTERLY REPORT (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2019 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num
April 5, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2019 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
January 14, 2019	10-Q	PTSC / Patriot Scientific Corp. FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2018 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num
October 15, 2018	10-Q	PTSC / Patriot Scientific Corp. FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2018 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 P
August 29, 2018	EX-21	List of subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Patriot Data Solutions Group, Inc. California
August 29, 2018	10-K	PTSC / Patriot Scientific Corp. ANNUAL REPORT (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2018 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATR
June 5, 2018	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 patriot8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2018 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction
April 18, 2018	DEFA14A	PTSC / Patriot Scientific Corp. FORM DEF A 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
April 18, 2018	DEF 14A	PTSC / Patriot Scientific Corp. DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
April 16, 2018	10-Q	PTSC / Patriot Scientific Corp. FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2018 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num
January 16, 2018	10-Q	PTSC / Patriot Scientific Corp. FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2017 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num
October 16, 2017	10-Q	PTSC / Patriot Scientific Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCI
August 29, 2017	10-K	PTSC / Patriot Scientific Corp. ANNUAL REPORT (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2017 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATR
August 29, 2017	EX-21	List of subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Plasma Scientific Corporation Delaware Patriot Data Solutions Group, Inc. California
May 4, 2017	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2017 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
April 13, 2017	10-Q	Patriot Scientific QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2017 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIO
March 15, 2017	DEF 14A	Patriot Scientific DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
January 17, 2017	10-Q	Patriot Scientific FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2016 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIO
January 6, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2016 PATRIOT SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
January 6, 2017	EX-10.1	Amended and Restated Employment Agreement dated December 30, 2016 by and between the Company and Clifford L. Flowers, incorporated by reference to Exhibit 10.1 to Form 8-K filed January 6, 2017 Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT ("Agreement") is by and between Patriot Scientific Corporation, a Delaware corporation ("Employer" or the "Company") and Clifford Flowers ("Executive"). WHEREAS, Executive is currently employed pursuant to an Employment Agreement dated September 17, 2007 (?Prior Agreement?). WHEREAS, the Employer
October 17, 2016	10-Q	Patriot Scientific FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2016 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT
August 29, 2016	EX-21	Youâve Exceeded the SECâs Traffic Limit Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Plasma Scientific Corporation Delaware Patriot Data Solutions Group, Inc. California
August 29, 2016	10-K	Patriot Scientific FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2016 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCIENTIFIC COR
August 16, 2016	EX-10.1	Agreement effective August 10, 2016 among Phoenix Digital Solutions, LLC, MMP Licensing LLC and Alliacense Limited, LLC, Exhibit 10.1 Confidential information has been omitted from portions of this document, indicated by [*], and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information. AGREEMENT This agreement ("Agreement") is entered into by and between: Phoenix Digital Solutions LLC, a Delaware limited liability company with i
August 16, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2016 PATRIOT SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
May 4, 2016	8-K	Patriot Scientific CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2016 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
April 14, 2016	10-Q	Patriot Scientific PATRIOT SCIENTIFIC CORPORATION QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT S
March 18, 2016	DEF 14A	Patriot Scientific DEFINITIVE NOTICE AND PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
March 8, 2016	PRE 14A	Patriot Scientific PATRIOT SCIENTIFIC CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
January 14, 2016	10-Q	PTSC / Patriot Scientific Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2015 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIO
October 15, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2015 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT
August 31, 2015	EX-21	Youâve Exceeded the SECâs Traffic Limit Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Plasma Scientific Corporation Delaware Patriot Data Solutions Group, Inc. California
August 31, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2015 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCIENTIFIC COR
May 21, 2015	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2015 PATRIOT SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
May 4, 2015	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2015 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
April 20, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2015 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 000-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
April 20, 2015	EX-99.1	Patriot Investor Relations Exhibit 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 x-102 Patriot Scientific Corporation Files Quarterly Report and Provides Legal Update CARLSBAD, Calif., April 14, 2015-(PR Newswire)-Patriot Scientific Corporation (OTCQB: PTSC) today announced it has filed its Report on Form 10-Q with the U.S. Securities and Exchange Commission for the quarterly period ended February 28, 20
April 14, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2015 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIO
March 9, 2015	DEF 14A	Patriot Scientific NOTICE AND PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
January 14, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2014 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIO
October 16, 2014	EX-10.10	Letter agreement dated October 10, 2014 between Phoenix Digital Solutions, LLC and Dominion Harbor Group, LLC, Exhibit 10.10 Confidential information has been omitted from portions of this document, indicated by [*], and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information. October 10, 2014 Carlton Johnson, Jr. Member Phoenix Digital Solutions, LLC 701 Palomar Road, Suite 170 Carlsbad, CA. 92011 Re: Advisory Service
October 16, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2014 PATRIOT SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
October 16, 2014	EX-99.1	Patriot Scientific Corporation Announces Retention of Dominion Harbor as Licensing Agent for MMP™ Portfolio Exhibit 99.1 Patriot Scientific Corporation Announces Retention of Dominion Harbor as Licensing Agent for MMP™ Portfolio CARLSBAD, Calif., Oct. 13, 2014 –(PRNewswire)–Patriot Scientific Corporation (OTCQB: PTSC) today announced that its joint venture Phoenix Digital Solutions (PDS), has entered into an agreement with Dominion Harbor Group, LLC (DHG) to provide licensing and enforcement services to
October 15, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2014 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT
August 19, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCIENTIFIC CORPOR
August 19, 2014	EX-21	Youâve Exceeded the SECâs Traffic Limit Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Plasma Scientific Corporation Delaware Patriot Data Solutions Group, Inc. California
July 30, 2014	EX-99.1	Patriot Scientific Corporation Announces Key New Agreement 07/28/14 Exhibit 99.1 Patriot Scientific Corporation Announces Key New Agreement 07/28/14 July 28, 2014 CARLSBAD, Calif., July 28, 2014 - (PR Newswire) - Patriot Scientific Corporation (OTCBB: PTSC) today announced that Phoenix Digital Solutions (PDS), Patriot’s joint venture that aggregates the ownership interests in the Moore Microprocessor Patent (MMP) PortfolioTM, has entered into an agreement with All
July 30, 2014	EX-10.10	Agreement effective July 24, 2014 among Phoenix Digital Solutions, LLC and Alliacense Limited, LLC, Exhibit 10.10 Confidential information has been omitted from portions of this document, indicated by [*], and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to this omitted information. AMENDED ALLIACENSE SERVICES AND NOVATION AGREEMENT 1. PARTIES The parties to this Agreement dated July 23, 2014 (the “Agreement”), are Alliacens
July 30, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2014 PATRIOT SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
May 1, 2014	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2014 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
April 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT S
March 11, 2014	DEF 14A	- PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
January 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT S
October 15, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) S QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2013 OR £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCI
August 23, 2013	EX-21	Youâve Exceeded the SECâs Traffic Limit Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Plasma Scientific Corporation Delaware Patriot Data Solutions Group, Inc. California
August 23, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCIENTIFIC CORPOR
May 9, 2013	8-K/A	Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders - AMENDMENT NO. 2 TO CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
May 3, 2013	8-K/A	Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders - AMENDMENT TO CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
May 2, 2013	8-K	Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders - CURRENT REPORT ON FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2013 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
April 15, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2013 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIO
March 11, 2013	DEF 14A	- PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
February 4, 2013	EX-10.8	Youâve Exceeded the SECâs Traffic Limit Exhibit 10.8 Confidential treatment has been requested for portions of this document indicated by [***], which portions are filed separately with the Commission. AGREEMENT This Agreement is entered into by and between PATRIOT SCIENTIFIC CORPORATION (“PTSC”), and TECHNOLOGY PROPERTIES LIMITED LLC (“TPL”) hereinafter sometimes collectively referred to as the “Parties”. WHEREAS, it is in the mutual i
February 4, 2013	EX-10.9	Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains
February 4, 2013	8-K/A	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - AMENDMENT TO FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
February 4, 2013	EX-10.7	Youâve Exceeded the SECâs Traffic Limit Exhibit 10.7 Confidential treatment has been requested for portions of this document indicated by [***], which portions are filed separately with the Commission. LICENSING PROGRAM SERVICES AGREEMENT Between ALLIACENSE LIMITED, LLC And PHOENIX DIGITAL SOLUTIONS, LLC 1. DEFINITIONS 2 2. CONDUCT OF THE PROJECT 4 3. COMPENSATION 5 4. TERM AND TERMINATION 5 5. REPRESENTATIONS AND WARRANTIES 6 6. DISPUT
January 14, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2012 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIO
October 15, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2012 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT
August 29, 2012	EX-21	Youâve Exceeded the SECâs Traffic Limit Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Plasma Scientific Corporation Delaware Patriot Data Solutions Group, Inc. California
August 29, 2012	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2012 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCIENTIFIC COR
July 27, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2012 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
July 27, 2012	EX-99.1	13 Companies Cited for Infringement of MMP Portfolio™ in ITC Complaint The MMP Portfolio™ Licensing Program is Dramatically Strengthened Via Markman Victory and Filing of ITC and District Court Complaints Exhibit 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 13 Companies Cited for Infringement of MMP Portfolio™ in ITC Complaint The MMP Portfolio™ Licensing Program is Dramatically Strengthened Via Markman Victory and Filing of ITC and District Court Complaints CARLSBAD, California – July 24, 2012 – (PR Newswire)-Patriot Scientific Corporation (OTCBB: PTSC - News) announced today
July 17, 2012	EX-10.8	Agreement effective July 11, 2012 between Technology Properties Limited, LLC and the Company, Exhibit 10.8 Confidential treatment has been requested for portions of this document indicated by [***], which portions are filed separately with the Commission. AGREEMENT This Agreement is entered into by and between PATRIOT SCIENTIFIC CORPORATION (“PTSC”), and TECHNOLOGY PROPERTIES LIMITED LLC (“TPL”) hereinafter sometimes collectively referred to as the “Parties”. WHEREAS, it is in the mutual i
July 17, 2012	EX-10.9	Agreement effective July 17, 2012 among Phoenix Digital Solutions, LLC, Alliacense Limited, LLC, Technology Properties Limited, LLC, and the Company, Exhibit 10.9 Confidential treatment has been requested for portions of this document indicated by [***], which portions are filed separately with the Commission. AGREEMENT This Agreement is entered into by and between PATRIOT SCIENTIFIC CORPORATION (“PTSC”), PHOENIX DIGITAL SOLUTIONS f/k/a P-Newco (“PDS”), and TECHNOLOGY PROPERTIES LIMITED LLC (“TPL”) hereinafter sometimes collectively referred to
July 17, 2012	EX-10.7	Licensing Program Services Agreement effective July 11, 2012 among Phoenix Digital Solutions, LLC, Alliacense Limited, LLC, Technology Properties Limited, LLC, and the Company, Exhibit 10.7 Confidential treatment has been requested for portions of this document indicated by [***], which portions are filed separately with the Commission. LICENSING PROGRAM SERVICES AGREEMENT Between ALLIACENSE LIMITED, LLC And PHOENIX DIGITAL SOLUTIONS, LLC 1. DEFINITIONS 2 2. CONDUCT OF THE PROJECT 4 3. COMPENSATION 5 4. TERM AND TERMINATION 5 5. REPRESENTATIONS AND WARRANTIES 6 6. DISPUT
July 17, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2012 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
April 16, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 patriot10q-022912.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C
February 14, 2012	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2012 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
January 17, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2011 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIO
December 21, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
October 17, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCI
October 7, 2011	EX-99.1	CARLSBAD and CUPERTINO, Calif., Oct. 7, 2011 /PRNewswire/ -- Patriot Scientific Corporation (OTCBB: Exhibit 99.1 CARLSBAD and CUPERTINO, Calif., Oct. 7, 2011 /PRNewswire/ - Patriot Scientific Corporation (OTCBB:PTSC.ob - News) and The TPL Group today announced that they have jointly reached an agreement to resolve and settle all claims and issues between them regarding their Joint Venture for the commercialization of the MMP Portfolio. The agreement includes mutual payments and mutual releases w
October 7, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2011 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
August 29, 2011	EX-10.6	Form of Indemnification Agreement by and between the Company and the Board of Directors, Exhibit 10.6 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of , 2011 by and between Patriot Scientific Corporation, a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided wit
August 29, 2011	EX-21	Youâve Exceeded the SECâs Traffic Limit Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Plasma Scientific Corporation Delaware Patriot Data Solutions Group, Inc. California
August 29, 2011	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2011 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCIENTIFIC COR
August 5, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2011 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
August 5, 2011	EX-99.1	Patriot Scientific Corporation Provides Update EXHIBIT 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 Patriot Scientific Corporation Provides Update CARLSBAD, Calif., August 3, 2011-(PR Newswire)-Patriot Scientific Corporation (OTCBB: PTSC - News) today issued the following letter to all stockholders. It has been over one year since we filed an action in the Superior Court of the State of California, County of Santa Clara ag
April 11, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT S
January 25, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2011 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
January 25, 2011	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2011 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
January 14, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2010 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIO
January 10, 2011	NT 10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [X] Form 10-D [] Form N-SAR [] Form N-CSR [] For Period Ended: November 30, 2010 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition
November 30, 2010	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
November 30, 2010	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
November 12, 2010	EX-99.1	Patriot Scientific Corporation Announces Annual Stockholders Meeting Details Exhibit 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 Patriot Scientific Corporation Announces Annual Stockholders Meeting Details CARLSBAD, Calif., November 9, 2010-(PR Newswire)-Patriot Scientific Corporation (OTCBB: PTSC - News) announced today that its Annual Meeting of Stockholders will be held on January 19, 2011. The Company?s Board of Directors has fixed the cl
November 12, 2010	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
November 9, 2010	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
November 9, 2010	EX-3.7.1	Amendment to bylaws of the Company, incorporated by reference to Exhibit 3.7.1 to our Current Report on Form 8-K dated November 4, 2010 Exhibit 3.7.1 CERTIFICATE OF AMENDMENT OF BYLAWS OF PATRIOT SCIENTIFIC CORPORATION I hereby certify that I am the duly elected, qualified and acting Secretary of Patriot Scientific Corporation, a Delaware corporation (the “Corporation”), and that the Board of Directors of the Corporation adopted a resolution amending the Bylaws of the Corporation at a duly held meeting of the Board of Directors on
October 28, 2010	EX-99.1	Company Addresses Fictitious News Release Regarding Cash Dividend EXHIBIT 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 Company Addresses Fictitious News Release Regarding Cash Dividend CARLSBAD, Calif., Oct. 27 /PRNewswire-FirstCall/ - Patriot Scientific Corporation (OTC Bulletin Board: PTSC - News) announced that a recently reported story by a major news organization regarding the Company?s planned payment of a cash dividend to sha
October 28, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
October 13, 2010	EX-99.1	Patriot Scientific Corporation Releases First Fiscal Quarter Report Exhibit 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 Patriot Scientific Corporation Releases First Fiscal Quarter Report CARLSBAD, Calif., October 12, 2010-(PR Newswire)-Patriot Scientific Corporation (OTCBB: PTSC - News) today reported the filing of its report on Form 10-Q for its first fiscal 2011 quarter ended August 31, 2010. For the three month period ended Augus
October 13, 2010	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
October 12, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCI
September 15, 2010	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State of other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
August 16, 2010	EX-21	Youâve Exceeded the SECâs Traffic Limit Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Plasma Scientific Corporation Delaware Patriot Data Solutions Group, Inc. California
August 16, 2010	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2010 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCIENTIFIC CORPOR
August 13, 2010	EX-99.1	Company Provides Update on Significant Activities Exhibit 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 Company Provides Update on Significant Activities CARLSBAD, Calif., August 13, 2010-(PR Newswire)-Patriot Scientific Corporation (OTCBB: PTSC - News) today issued an update on significant business matters. To All Shareholders, Prospective Investors, and Stakeholders in Patriot Scientific Corporation, As many of you
August 13, 2010	EX-99.2	Patriot Scientific Corporation Provides Litigation Update Exhibit 99.2 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 Patriot Scientific Corporation Provides Litigation Update CARLSBAD, Calif., August 13, 2010-(PR Newswire)-Patriot Scientific Corporation (OTCBB: PTSC - News) today reported that it has withdrawn from discussions aimed at settling its outstanding actions against The Technology Properties Limited Group, LLC (TPL) and
August 13, 2010	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
July 28, 2010	EX-99.1	MMP Portfolio™ Prevails In Latest Patent Reexamination Exhibit 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 News Release MMP Portfolio? Prevails In Latest Patent Reexamination Carlsbad, CA and Cupertino, CA ? July 27, 2010 ? Patriot Scientific Corporation (OTC Bulletin Board: PTSC News), The TPL Group and Alliacense today announced their latest success in overcoming attempts to challenge the validity of the MMP Portfolio?
July 28, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
July 27, 2010	EX-99.2	Patriot Data Solutions Group Signs Reseller Agreement with SRA International Exhibit 99.2 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 Patriot Data Solutions Group Signs Reseller Agreement with SRA International CARLSBAD, Calif., July 21, 2010-(PR Newswire)-Patriot Scientific Corporation (OTCBB: PTSC - News) today reported that its wholly owned subsidiary, Patriot Data Solutions Group (PDSG), has entered into a strategic partnership agreement with
July 27, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2010 Patriot Scientific Co UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
July 27, 2010	EX-99.1	ENFORSYS AND PATRIOT DATA SOLUTIONS TEAM TO ENABLE NEW JERSEY LAW ENFORCEMENT AGENCIES TO SUCCESSFULLY SHARE INFORMATION Exhibit 99.1 Contact: Kim Larkin Larkin Communications for PDSG Office: (703) 250-3590, x102 Mobile (202) 391-5205 [email protected] ENFORSYS AND PATRIOT DATA SOLUTIONS TEAM TO ENABLE NEW JERSEY LAW ENFORCEMENT AGENCIES TO SUCCESSFULLY SHARE INFORMATION July 20, 2010 ? Enforsys, Inc. (?Enforsys?) and Patriot Data Solutions Group, Inc. (?PDSG?) announced today that they have successfully teame
July 9, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2010 Patriot Scientific Cor UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
July 9, 2010	EX-99.1	Patriot Data Solutions Group Affirms Go To Market Strategy Exhibit 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 Patriot Data Solutions Group Affirms Go To Market Strategy CARLSBAD, Calif., July 8, 2010- (PR Newswire)-Patriot Scientific Corporation (OTCBB: PTSC - News) today reported initial success of the go-to-market strategy for its wholly owned subsidiary, Patriot Data Solutions Group (PDSG). “With the assistance of strate
April 27, 2010	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
April 27, 2010	EX-99.1	Patriot Scientific Corporation Files Complaint against The TPL Group Exhibit 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 Patriot Scientific Corporation Files Complaint against The TPL Group CARLSBAD, Calif., April 26, 2010-(PR Newswire)-Patriot Scientific Corporation (OTCBB: PTSC - News) today reported that on April 22, 2010 it filed an action in the Superior Court of the State of California, County of Santa Clara against Technology P
April 13, 2010	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
April 9, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 patriot10q-022810.htm PATRIOT SCIENTIFIC CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transi
February 2, 2010	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
January 12, 2010	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2010 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
January 12, 2010	EX-99.1	Patriot Scientific Corporation Releases Second Fiscal Quarter Report Exhibit 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 Patriot Scientific Corporation Releases Second Fiscal Quarter Report CARLSBAD, Calif., January 11, 2010-(PR Newswire)-Patriot Scientific Corporation (OTCBB: PTSC - News) today reported the filing of its report on Form 10-Q for its second fiscal 2010 quarter ended November 30, 2009. For the three and six month period
January 11, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2009 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIO
December 8, 2009	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2009 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
December 8, 2009	EX-99.1	PATRIOT SCIENTIFIC CORPORATION ANNOUNCES NEW DIRECTOR Exhibit 99.1 Contact: Patriot Investor Relations [email protected] 760-547-2700 ext. 102 PATRIOT SCIENTIFIC CORPORATION ANNOUNCES NEW DIRECTOR CARLSBAD, Calif., Dec. 7 /PRNewswire-FirstCall/ - Patriot Scientific Corporation (OTC Bulletin Board: PTSC - News) announced that Dharmesh Mistry would be joining its Board of Directors and will serve as chair of the Technology Committee. Mr. Mistry has over 16 y
December 8, 2009	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
November 12, 2009	EX-99.1	PTSC STREAMLINES SUBSIDIARY OPERATIONS Reduces Operating Expenses While Reaffirming Core Focus Exhibit 99.1 PTSC STREAMLINES SUBSIDIARY OPERATIONS Reduces Operating Expenses While Reaffirming Core Focus CARLSBAD, Calif., Nov. 12 /PRNewswire-FirstCall/ - Patriot Scientific Corporation (OTC Bulletin Board: PTSC - News) announced it has taken measures to reduce expenses at its wholly owned subsidiary Patriot Data Solutions Group, Inc. (“PDSG”), while reaffirming its commitment to provide state
November 12, 2009	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2009 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
October 9, 2009	10-Q	STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 patriot10q-083109.htm PATRIOT SCIENTIFIC CORPORATION FORM 10-Q STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2009 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tr
October 9, 2009	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2009 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
October 9, 2009	EX-99.1	PATRIOT SCIENTIFIC CORPORATION ANNOUNCES MAJOR REORGANIZATION EXHIBIT 99.1 Contact: Angela Hartley Investor Relations [email protected] 760-547-2700 ext. 102 PATRIOT SCIENTIFIC CORPORATION ANNOUNCES MAJOR REORGANIZATION October 9, 2009 - CARLSBAD, Calif.- Patriot Scientific Corporation (OTC BB:PTSC) announced a major reorganization today. Rick Goerner has been relieved from his position as Chief Executive Officer and President of Patriot Scientific Corporation (“P
August 19, 2009	EX-99.1	[PTSC]- Patriot Scientific Corporation FY '09 Year End Shareholder Call Monday, August 17, 2009 Exhibit 99.1 [PTSC]- Patriot Scientific Corporation FY '09 Year End Shareholder Call Monday, August 17, 2009 Officers: Rick Goerner; Patriot Scientific; President & CEO Cliff Flowers; Patriot Scientific; CFO Paul Bibeau; Patriot Scientific; VP, Business Development Presentation Operator: At this time, I would like to welcome everyone to the Patriot Scientific's Fiscal 2009 Fourth Quarter and Year-
August 19, 2009	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2009 Patriot Scientific Corporation (Exact name of registrant as specified in its charter) Delaware 0-22182 84-1070278 (State or other jurisdiction of incorporation) (Commission File Number) (I.
August 14, 2009	EX-3.3.8	Certificate of Amendment to the Certificate of Incorporation of Patriot Scientific Corporation, as filed with the Delaware Secretary of State on March 18, 2009, Exhibit 3.3.8 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF PATRIOT SCIENTIFIC CORPORATION Patriot Scientific Corporation, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify that: I. The amendment to the Corporation?s Certificate of Incorporation set forth below was duly adopted in accordance w
August 14, 2009	EX-21	Youâve Exceeded the SECâs Traffic Limit Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Jurisdiction Plasma Scientific Corporation Delaware Patriot Data Solutions Group, Inc. California
August 14, 2009	EX-99.11	Form of Non-Qualified Stock Option Agreement to the Company’s 2006 Stock Option Plan, Exhibit 99.11 NON-QUALIFIED STOCK OPTION AGREEMENT THIS NON-QUALIFIED STOCK OPTION AGREEMENT ("Agreement") is made by and between Patriot Scientific Corporation, a Delaware corporation (the "Corporation"), and (the "Optionee"). NOW, THEREFORE, in consideration of the mutual benefit to be derived herefrom, the Corporation and Optionee agree as follows: 1. Grant of Option. The Corporation hereby gra
August 14, 2009	EX-99.10	Form of Incentive Stock Option Agreement to the Company’s 2006 Stock Option Plan, Exhibit 99.10 INCENTIVE STOCK OPTION AGREEMENT THIS INCENTIVE STOCK OPTION AGREEMENT ("Agreement") is made by and between Patriot Scientific Corporation, a Delaware corporation, (the "Corporation"), and (the "Optionee"). NOW, THEREFORE, in consideration of the mutual benefit to be derived herefrom, the Corporation and Optionee agree as follows: 1. Grant of Option. The Corporation hereby grants to
August 14, 2009	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2009 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-22182 PATRIOT SCIENTIFIC COR

CPMV / Mosaic ImmunoEngineering, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)